Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d
about
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infectionClinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyRationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDSThe 2015 Clinical Guidelines for the Diagnosis and Treatment of HIV/AIDS in HIV-Infected KoreansEfficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDSDolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIVResistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceHIV Drug Resistance: Problems and PerspectivesClinical use of HIV integrase inhibitors: a systematic review and meta-analysisHistone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial TherapyWhat's new for antiretroviral treatment in women with HIVNoninfectious Diarrhea in HIV Seropositive Individuals: a Review of Prevalence Rates, Etiology, and Management in the Era of Combination Antiretroviral TherapyHIV integrase inhibitors: a new era in the treatment of HIV.Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation CohortCritical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.Novel approaches to HIV therapy.Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase InhibitorsSingle-Tablet Regimens in HIV TherapyResistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistatA cutting-edge view on the current state of antiviral drug development.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.HIV-associated lipodystrophy: impact of antiretroviral therapy.Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 InfectionWhat if HIV were unable to develop resistance against a new therapeutic agent?Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter TrialEPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment.Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.
P2860
Q26750406-59AF99C5-F1C8-4E44-B09D-9649C2A858AEQ26771182-D2FCE59E-075D-45D2-B1D2-94FB520017C6Q26777251-0FF74FA8-B968-45B7-BE4B-B4BE334D33E8Q26781379-F30EC56C-DB94-4E56-8D94-7274CA14009EQ26783253-46FF43AC-366B-4B4C-989C-9C29EC574EE9Q26799712-5A191899-146E-4E4B-8F92-9E48C693F6BCQ26801286-1441C350-B63C-4171-95A4-D3450DB43B67Q26864534-97A64875-B371-4934-A1CE-5422F088EAABQ28484930-FB18BC65-3D6F-4D52-AE8B-2F809D9A8F73Q28537694-788D8290-7833-47CF-9CFD-4A6527CA3231Q28552210-63B47105-6824-488D-8DE4-4B3C8AFF3CA1Q30391322-E6E1E98A-C2E2-4341-9F74-8F80F04371CBQ30609066-8AE7F720-7255-45FB-95E2-EA54BC644AADQ30956943-6EA90538-CFCC-4D31-9CBE-1F4925C54857Q31110946-E9594FDD-98E2-4289-85F5-0F28B97E496DQ33680234-4C9F0F8A-B026-4F10-AE39-E389E7F7D3E5Q33767281-BB4C6616-F781-451D-83F1-392408D07725Q33777819-3140DFA2-DCDD-4E78-8BF0-4C2B5BF93155Q33817410-D30CA152-3E44-4D7B-B1FA-5FB0A1FAF813Q33939069-AC0FE23B-8FD6-4010-8EB4-6C0AB6E967EBQ33939110-4419F73B-FD0D-44D3-8B59-5D5875393372Q33963458-F43E6DCC-234F-4E0E-BFF8-222F334B6E5EQ33997420-CF3B67D7-B926-466D-91A3-485B7BD70466Q34036018-4EB28242-A71F-42AC-9E95-621C637F1438Q34134900-DB92EFFD-5D61-404B-ABB0-6805F201C48EQ34478840-9CC7A577-9135-4809-A965-959FAF2F3E49Q34655845-C4F4E252-6248-48E2-AF4F-B44D590DD0D0Q34726183-BC943E1B-29A3-4E8C-A6CF-DA1E12876AF7Q34736194-890F24FC-7902-47C0-97D0-8776F00DEFCDQ34976284-AC3FEDB8-217F-42CF-AD74-C069B3786372Q35051393-A8119488-98D7-4D14-B148-D62ACCB46D0AQ35169003-DD7C9797-5BCB-4024-A5FA-872208E9CC0AQ35186842-EA7EBE8C-2199-4F89-B0BB-E32E0B250777Q35546757-A96810CE-6DB2-42DF-BD80-4CEF63308C4CQ35566732-5056B901-CA42-4CC6-84C0-0AFEEDF7D8D3Q35833324-DB5930A9-90D9-43BB-9BFA-E932935A143CQ35885190-07D6D94F-8A7B-44B5-BD3A-35254389D5F2Q35921909-A4F8E569-AC61-444E-B5C7-917A95296E65Q36281109-0CDFE857-E2E2-4C8A-AE08-C2B4A7041579Q36288425-9F814A99-19B1-46E5-B79D-44A4577AD141
P2860
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, d
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Co-formulated elvitegravir, co ...... V-1 infection: a randomised, d
@en
Co-formulated elvitegravir, co ...... V-1 infection: a randomised, d
@nl
type
label
Co-formulated elvitegravir, co ...... V-1 infection: a randomised, d
@en
Co-formulated elvitegravir, co ...... V-1 infection: a randomised, d
@nl
prefLabel
Co-formulated elvitegravir, co ...... V-1 infection: a randomised, d
@en
Co-formulated elvitegravir, co ...... V-1 infection: a randomised, d
@nl
P2093
P1433
P1476
Co-formulated elvitegravir, co ...... V-1 infection: a randomised, d
@en
P2093
Andrew K Cheng
Brian P Kearney
Edwin DeJesus
GS-236-0103 Study Team
Javier Szwarcberg
Jean-Michel Molina
Joseph Gathe
Keith Henry
Kirsten White
Kitty Yale
P304
P356
10.1016/S0140-6736(12)60918-0
P407
P577
2012-06-01T00:00:00Z